Literature DB >> 24072712

Herpesvirus-associated ubiquitin-specific protease (HAUSP) modulates peroxisome proliferator-activated receptor γ (PPARγ) stability through its deubiquitinating activity.

Kyeong Won Lee1, Jin Gu Cho, Chul Min Kim, A Young Kang, Min Kim, Byung Yong Ahn, Sung Soo Chung, Key-Hwan Lim, Kwang-Hyun Baek, Jong-Hyuk Sung, Kyong Soo Park, Sang Gyu Park.   

Abstract

The peroxisome proliferator-activated receptor γ (PPARγ) is a central regulator of adipogenesis and modulates glucose and lipid metabolism. In this study, herpesvirus-associated ubiquitin-specific protease (HAUSP) was isolated as a binding partner of PPARγ. Both endogenous and exogenous PPARγ associated with HAUSP in co-immunoprecipitation analysis. HAUSP, but not the catalytically inactive HAUSP C223S mutant, increased the stability of both endogenous and exogenous PPARγ through its deubiquitinating activity. Site-directed mutagenesis experiments showed that the Lys(462) residue of PPARγ is critical for ubiquitination. HBX 41,108, a specific inhibitor of HAUSP, abolished the increase in PPARγ stability induced by HAUSP. In addition, knockdown of endogenous HAUSP using siRNA decreased PPARγ protein levels. HAUSP enhanced the transcriptional activity of both exogenous and endogenous PPARγ in luciferase activity assays. Quantitative RT-PCR analysis showed that HAUSP increased the transcript levels of PPARγ target genes in HepG2 cells, resulting in the enhanced uptake of glucose and fatty acids, and vice versa, upon siRNA knockdown of HAUSP. In vivo analysis using adenoviruses confirmed that HAUSP, but not the HAUSP C223S mutant, decreased blood glucose and triglyceride levels, which are associated with the increased expression of endogenous PPARγ and lipid accumulation in the liver. Our results demonstrate that the stability and activity of PPARγ are modulated by the deubiquitinating activity of HAUSP, which may be a target for the development of anti-diabetic drugs.

Entities:  

Keywords:  Deubiquitination; Diabetes; Glucose Metabolism; Metabolism; Peroxisome Proliferator-activated receptor (PPAR)

Mesh:

Substances:

Year:  2013        PMID: 24072712      PMCID: PMC3829140          DOI: 10.1074/jbc.M113.496331

Source DB:  PubMed          Journal:  J Biol Chem        ISSN: 0021-9258            Impact factor:   5.157


  48 in total

1.  Degradation of the peroxisome proliferator-activated receptor gamma is linked to ligand-dependent activation.

Authors:  S Hauser; G Adelmant; P Sarraf; H M Wright; E Mueller; B M Spiegelman
Journal:  J Biol Chem       Date:  2000-06-16       Impact factor: 5.157

2.  Interferon-gamma-induced regulation of peroxisome proliferator-activated receptor gamma and STATs in adipocytes.

Authors:  K J Waite; Z E Floyd; P Arbour-Reily; J M Stephens
Journal:  J Biol Chem       Date:  2000-12-05       Impact factor: 5.157

3.  PPAR-gamma dependent and independent effects on macrophage-gene expression in lipid metabolism and inflammation.

Authors:  A Chawla; Y Barak; L Nagy; D Liao; P Tontonoz; R M Evans
Journal:  Nat Med       Date:  2001-01       Impact factor: 53.440

4.  Diabetic KKAy mice exhibit increased hepatic PPARgamma1 gene expression and develop hepatic steatosis upon chronic treatment with antidiabetic thiazolidinediones.

Authors:  M Bedoucha; E Atzpodien; U A Boelsterli
Journal:  J Hepatol       Date:  2001-07       Impact factor: 25.083

5.  Effects of ligand activation of peroxisome proliferator-activated receptor gamma in human prostate cancer.

Authors:  E Mueller; M Smith; P Sarraf; T Kroll; A Aiyer; D S Kaufman; W Oh; G Demetri; W D Figg; X P Zhou; C Eng; B M Spiegelman; P W Kantoff
Journal:  Proc Natl Acad Sci U S A       Date:  2000-09-26       Impact factor: 11.205

6.  Anticancer effects of thiazolidinediones are independent of peroxisome proliferator-activated receptor gamma and mediated by inhibition of translation initiation.

Authors:  S S Palakurthi; H Aktas; L M Grubissich; R M Mortensen; J A Halperin
Journal:  Cancer Res       Date:  2001-08-15       Impact factor: 12.701

7.  Up-regulation of peroxisome proliferator-activated receptors (PPAR-alpha) and PPAR-gamma messenger ribonucleic acid expression in the liver in murine obesity: troglitazone induces expression of PPAR-gamma-responsive adipose tissue-specific genes in the liver of obese diabetic mice.

Authors:  R A Memon; L H Tecott; K Nonogaki; A Beigneux; A H Moser; C Grunfeld; K R Feingold
Journal:  Endocrinology       Date:  2000-11       Impact factor: 4.736

8.  An increase in liver PPARγ2 is an initial event to induce fatty liver in response to a diet high in butter: PPARγ2 knockdown improves fatty liver induced by high-saturated fat.

Authors:  Tomomi Yamazaki; Sayaka Shiraishi; Kyoko Kishimoto; Shinji Miura; Osamu Ezaki
Journal:  J Nutr Biochem       Date:  2010-08-30       Impact factor: 6.048

9.  Anti-diabetic drugs inhibit obesity-linked phosphorylation of PPARgamma by Cdk5.

Authors:  Jang Hyun Choi; Alexander S Banks; Jennifer L Estall; Shingo Kajimura; Pontus Boström; Dina Laznik; Jorge L Ruas; Michael J Chalmers; Theodore M Kamenecka; Matthias Blüher; Patrick R Griffin; Bruce M Spiegelman
Journal:  Nature       Date:  2010-07-22       Impact factor: 49.962

10.  Effect of a peroxisome proliferator-activated receptor gamma sumoylation mutant on neointimal formation after balloon injury in rats.

Authors:  Soo Lim; Byung Yong Ahn; Sung Soo Chung; Ho Seon Park; Bong Jun Cho; Min Kim; Sung Hee Choi; In Kyu Lee; Sang-Won Lee; Soo Joon Choi; Chin Ha Chung; Young Min Cho; Hong Kyu Lee; Kyong Soo Park
Journal:  Atherosclerosis       Date:  2009-03-11       Impact factor: 5.162

View more
  8 in total

Review 1.  USP7: Structure, substrate specificity, and inhibition.

Authors:  Alexandra Pozhidaeva; Irina Bezsonova
Journal:  DNA Repair (Amst)       Date:  2019-02-16

2.  USP7 attenuates hepatic gluconeogenesis through modulation of FoxO1 gene promoter occupancy.

Authors:  Jessica A Hall; Mitsuhisa Tabata; Joseph T Rodgers; Pere Puigserver
Journal:  Mol Endocrinol       Date:  2014-04-02

3.  Myeloma cells shift osteoblastogenesis to adipogenesis by inhibiting the ubiquitin ligase MURF1 in mesenchymal stem cells.

Authors:  Zhiqiang Liu; Huan Liu; Jin He; Pei Lin; Qiang Tong; Jing Yang
Journal:  Sci Signal       Date:  2020-05-26       Impact factor: 8.192

4.  MD001, a Novel Peroxisome Proliferator-activated Receptor α/γ Agonist, Improves Glucose and Lipid Metabolism.

Authors:  Seok-Ho Kim; Shin Hee Hong; Young-Joon Park; Jong-Hyuk Sung; Wonhee Suh; Kyeong Won Lee; Kiwon Jung; Changjin Lim; Jin-Hee Kim; Hyoungsu Kim; Kyong Soo Park; Sang Gyu Park
Journal:  Sci Rep       Date:  2019-02-07       Impact factor: 4.379

5.  Suppression of USP7 induces BCR-ABL degradation and chronic myelogenous leukemia cell apoptosis.

Authors:  Shuoyi Jiang; Xiaoge Wang; Yuanming He; Hongbiao Huang; Biyin Cao; Zubin Zhang; Jinbao Liu; Qi Wang; Zhenqian Huang; Xinliang Mao
Journal:  Cell Death Dis       Date:  2021-05-07       Impact factor: 8.469

6.  Ubiquitin specific protease 19 involved in transcriptional repression of retinoic acid receptor by stabilizing CORO2A.

Authors:  Key-Hwan Lim; Jong-Ho Choi; Jung-Hyun Park; Hyeon-Ju Cho; Jang-Joon Park; Eung-Ji Lee; Lan Li; Young-Kil Choi; Kwang-Hyun Baek
Journal:  Oncotarget       Date:  2016-06-07

Review 7.  Re-highlighting the action of PPARγ in treating metabolic diseases.

Authors:  Sung Hee Choi; Sung Soo Chung; Kyong Soo Park
Journal:  F1000Res       Date:  2018-07-24

8.  Emerging insights into HAUSP (USP7) in physiology, cancer and other diseases.

Authors:  Seemana Bhattacharya; Dipankar Chakraborty; Malini Basu; Mrinal K Ghosh
Journal:  Signal Transduct Target Ther       Date:  2018-06-29
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.